



Q3 FY26 Earnings

Cardinal Health, Inc.

April 30, 2026

Cautions Concerning Forward-Looking Statements

This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include our ability to manage uncertainties associated with the pricing of branded pharmaceuticals including those arising from proposed or final regulatory changes, the risk that we may fail to achieve our strategic objectives, including the operation of recently acquired entities and the continued execution of the GMPD Improvement Plan initiatives; risks and uncertainties related to tariffs, including the risk that we may not be able to offset increased costs or that we will lose customers if our competitors do not increase price on impacted products to the same extent that we do, competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts, whether due to price increases or otherwise; risks associated with litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act; the risk that events outside of our control, such as weather or geopolitical events, including the recent conflict with Iran, may impact costs for our products or may cause supply delays or shortages or manufacturing delays that impact our cost and ability to fulfill customer demand; and the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8K reports and exhibits to those reports. This presentation reflects management's views as of April 30, 2026. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed. Cardinal Health provides definitions and reconciliations of non-GAAP financial measures and their most directly comparable GAAP financial measures at ir.cardinalhealth.com





Q3 Results

Q3 FY26 financial summary

	GAAP Basis (\$M) Q3 FY26	Non-GAAP Basis (\$M) Q3 FY26
Revenue <i>% change</i>	\$60,940 11%	N/A
Gross Margin <i>% change</i>	\$2,498 18%	\$2,498 18%
SG&A <i>% change</i>	\$1,542 17%	\$1,542 17%
Operating Earnings <i>% change</i>	\$509 (30%)	\$956 18%
Interest and Other¹ <i>% change</i>	\$117 80%	N/A
Net Earnings² <i>% change</i>	\$399 (21%)	\$750 32%
Diluted EPS² <i>% change</i>	\$1.69 (20%)	\$3.17 35%

¹The sum of "other (income)/expense, net" and "interest expense, net"

²Attributable to Cardinal Health, Inc.

Please see appendix for GAAP to Non-GAAP reconciliations.



Pharmaceutical and Specialty Solutions

Q3 FY26 results

	Q3 FY26 (\$M)	Q3 FY25 (\$M)	YoY change
Revenue	\$56,111	\$50,433	11%
Segment profit	\$784	\$662	18%
Segment profit margin	1.40%	1.31%	9 bps

Drivers:

Revenue

- + Brand and specialty pharmaceutical sales growth from existing customers

Segment profit

- + Brand and specialty products
- + Generics program

The sum of the components and certain computations may reflect rounding adjustments.



Global Medical Products and Distribution

Q3 FY26 results

	Q3 FY26 (\$M)	Q3 FY25 (\$M)	YoY change
Revenue	\$3,148	\$3,160	–
Segment profit	\$25	\$39	(36%)
Segment profit margin	0.79%	1.23%	(44) bps

Drivers:

Revenue

- Distribution volumes
- + Cardinal Health brand

Segment profit

- Net impact of tariffs

The sum of the components and certain computations may reflect rounding adjustments.



Other: NPHS, at-Home Solutions and OptiFreight

Q3 FY26 results

	Q3 FY26 (\$M)	Q3 FY25 (\$M)	YoY change
Revenue	\$1,706	\$1,304	31%
Segment profit	\$179	\$134	34%
Segment profit margin	10.49%	10.28%	21 bps

Drivers:

Revenue

+ Growth across the three operating segments

Segment profit

+ Growth across the three operating segments

The sum of the components and certain computations may reflect rounding adjustments.





FY26 Outlook

FY26 financial expectations

	FY26 outlook	FY25 actual
Non-GAAP EPS	\$10.70 - \$10.80 <i>Previously \$10.15 - \$10.35</i>	\$8.24
Interest and Other	~\$340M <i>Previously \$325M</i>	\$174M
Non-GAAP ETR	~19% <i>Previously 21% - 23%</i>	23.3%
Diluted weighted average shares outstanding	~237M <i>Previously 237M - 238M</i>	242M
Share repurchases	~\$1B <i>Previously ~\$750M</i>	\$750M
Capital expenditures	\$600M - \$650M	\$547M
Non-GAAP adjusted free cash flow	\$3.3B - \$3.7B <i>Previously \$3.0B - \$3.5B</i>	\$2.5B

Bold indicates a **change** to the FY26 outlook provided at Q2 FY26 earnings release on February 5, 2026

The company does not provide forward-looking expectations on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "use of non-GAAP measures" in the financial appendix at the end of this presentation for additional explanation.



FY26 segment guidance

Revenue and segment profit

Pharmaceutical and Specialty Solutions

Revenue growth of **15% to 17%**

Segment profit growth of **22% to 23%**

Previously growth of 20% to 22%

Other: at-Home Solutions NPHS, OptiFreight Logistics

Revenue growth of **26% to 28%**

Segment profit growth of **36% to 38%**

Previously growth of 33% to 35%

Global Medical Products and Distribution

Revenue growth of **1% to 3%**


Segment profit of **~\$150M**

Bold indicates a **change** to the FY26 outlook provided at Q2 FY26 earnings release on February 5, 2026


Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions, and OptiFreight® Logistics, which are not significant enough individually to require reportable segment disclosure.



Strategic priorities



Supporting community-based physicians with a comprehensive model



Adding Solaris Health to The Specialty Alliance

Transaction completed in early November

Solaris Health overview

Country's leading urology managed service organization (MSO) with **750+** providers across **250** practice locations in **14** states

Diverse revenue streams underpinned by a national MSO infrastructure

Enables urology providers to focus more time on their patients through clinical research, streamlined practice coordination and improved back-office support

Growing The Specialty Alliance

- 1** Bolsters CAH's leadership in the urology specialty therapeutic area
- 2** Strengthens The Specialty Alliance's **leading multi-specialty platform** and **resilient business model** by adding scale and extending reach to new markets
- 3** CAH's MSO platforms now reach **~3,000 community providers** across **33 states**



Disciplined capital allocation framework

Table stakes



Investing back into the business to drive organic growth



Maintain investment grade balance sheet



Baseline return of capital to shareholders

- Continue to grow the dividend
- Baseline share repurchases

Opportunistic levers



Disciplined and targeted M&A



Additional opportunistic share repurchases

FY26 progress

\$385M in YTD capex

Achieved targeted leverage range ahead of schedule¹

- \$600M of debt repayments YTD, including \$100M early term loan payment in Q3

~\$1.125B in baseline capital returned to shareholders

- \$750M in baseline share repurchases completed
- ~\$375M in dividend payments

Completed the acquisition of Solaris Health

- Completed 7 tuck-in acquisitions in The Specialty Alliance
- Continue to evaluate tuck-in M&A in Specialty and our growth businesses

~\$250M of additional opportunistic share repurchases


¹The company maintains a targeted leverage range of 2.75x to 3.25x Adjusted Debt to EBITDA as defined by Moody's Ratings. The company achieved 3.0x leverage as of March 31, 2026 per internal estimates



Compelling investment thesis



Consistent track record



Unique breadth of capabilities



Resilient model



Strong core Pharma



Specialty key opportunity



Higher-margin growth businesses



Progress with GMPD turnaround



Increasing cash flow generation



Disciplined capital allocation



12% to 14% non-GAAP EPS long-term CAGR



Appendix

Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation¹

	Gross Margin		SG&A ²		Operating Earnings		Earnings Before Income Taxes		Provision for Income Taxes		Net (Earnings)/Loss Attributable to Non-controlling Interests		Net Earnings ³		Effective Tax Rate		Diluted EPS ³	
	Margin	Growth Rate	SG&A ²	Growth Rate	Operating Earnings	Growth Rate	Income Taxes	Income Taxes	Income Taxes	Income Taxes	Net Earnings ³	Net Earnings ³	Growth Rate	Tax Rate	Diluted EPS ³	Growth Rate	Diluted EPS ³	Growth Rate
<i>(in millions, except per common share amounts)</i>																		
Third Quarter 2026																		
GAAP	\$ 2,498	18 %	\$ 1,542	17 %	\$ 509	(30)%	\$ 392	\$ 12	\$ 19	\$ 399	(21)%	3.1 %	\$ 1.69	(20)%				
Restructuring and employee severance	—	—	—	—	25	—	25	6	—	19	—	0.08	—					
Amortization and other acquisition-related costs	—	—	—	—	114	—	114	43	—	71	—	0.30	—					
Acquisition-related cash & share-based compensation costs	—	—	—	—	112	—	112	4	—	108	—	0.46	—					
Impairments and (gain)/loss on disposal of assets, net ⁴	—	—	—	—	185	—	185	22	(23)	140	—	0.59	—					
Litigation (recoveries)/charges, net	—	—	—	—	11	—	11	(2)	—	13	—	0.06	—					
Non-GAAP	\$ 2,498	18 %	\$ 1,542	17 %	\$ 956	18 %	\$ 840	\$ 86	\$ (4)	\$ 750	32 %	10.2 %	\$ 3.17	35 %				
Third Quarter 2025																		
GAAP	\$ 2,123	10 %	\$ 1,315	4 %	\$ 730	98 %	\$ 665	\$ 157	\$ (2)	\$ 506	94 %	23.6 %	\$ 2.10	96 %				
Restructuring and employee severance	—	—	—	—	28	—	28	7	—	21	—	0.09	—					
Amortization and other acquisition-related costs	—	—	—	—	152	—	152	34	(2)	116	—	0.48	—					
Acquisition-related cash & share-based compensation costs	—	—	—	—	20	—	20	1	(4)	15	—	0.06	—					
Impairments and (gain)/loss on disposal of assets, net	—	—	—	—	(17)	—	(17)	(4)	—	(13)	—	(0.06)	—					
Litigation (recoveries)/charges, net	—	—	—	—	(105)	—	(105)	(27)	—	(78)	—	(0.32)	—					
Non-GAAP	\$ 2,122	10 %	\$ 1,315	4 %	\$ 807	21 %	\$ 741	\$ 166	\$ (7)	\$ 568	11 %	22.4 %	\$ 2.35	13 %				

¹ For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.

² Distribution, selling, general and administrative expenses.

³ Attributable to Cardinal Health, Inc.

⁴ For the three months ended March 31, 2026, impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of \$184 million related to the Navista & ION reporting unit within the Pharma segment. For fiscal 2026, the estimated net tax benefit related to the impairments is \$23 million and is included in the annual effective tax rate. The portion of the goodwill impairment charge attributable to noncontrolling interests is \$23 million.

The sum of the components and certain computations may reflect rounding adjustments.

We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.



Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation¹

	Gross Margin	Gross Growth Rate	SG&A ²	SG&A ² Growth Rate	Operating Earnings	Operating Growth Rate	Earnings Before Income Taxes	Provision for Income Taxes	Net Earnings Attributable to Non-Controlling Interests	Net Earnings ³	Net Earnings ³ Growth Rate	Effective Tax Rate	Diluted EPS ³	Diluted EPS ³ Growth Rate
(in millions, except per common share amounts)														
Fiscal Year 2025														
GAAP	\$ 8,168	10 %	\$ 5,382	8 %	\$ 2,275	83%	\$ 2,101	\$ 532	\$ (8)	\$ 1,561	83%	25.3 %	\$ 6.45	87%
Restructuring and employee severance	-		-		88		88	21		67			0.28	
Amortization and other acquisition-related costs	-		-		464		464	104		360			1.49	
Acquisition-related cash & share-based compensation costs	-		-		126		126	1		125			0.51	
Impairments and (gain)/loss on disposal of assets, net	-		-		18		18	5		13			0.05	
Litigation (recoveries)/charges, net	-		-		(185)		(185)	(54)		(131)			(0.54)	
Non-GAAP	\$ 8,168	10 %	\$ 5,382	8 %	\$ 2,786	15 %	\$ 2,612	\$ 609	\$ (8)	\$ 1,995	7 %	23.3 %	\$ 8.24	9 %

¹ For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.

² Distribution, selling, general and administrative expenses.

³ Attributable to Cardinal Health, Inc.

The sum of the components and certain computations may reflect rounding adjustments.

We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.



Cardinal Health, Inc. and Subsidiaries
Segment Information

Third Quarter

(in millions)	Pharmaceutical and Specialty Solutions		Global Medical Products and Distribution		Other	
	2026	2025	2026	2025	2026	2025
Revenue						
Amount	\$ 56,111	\$ 50,433	\$ 3,148	\$ 3,160	\$ 1,706	\$ 1,304
Growth rate	11 %	— %	— %	2 %	31 %	13 %
Segment profit						
Amount	\$ 784	\$ 662	\$ 25	\$ 39	\$ 179	\$ 134
Growth rate	18 %	14 %	(36) %	77 %	34 %	22 %
Segment profit margin	1.40 %	1.31 %	0.79 %	1.23 %	10.49 %	10.28 %

Year-to-Date

(in millions)	Pharmaceutical and Specialty Solutions		Global Medical Products and Distribution		Other	
	2026	2025	2026	2025	2026	2025
Revenue						
Amount	\$ 175,985	\$ 149,272	\$ 9,591	\$ 9,437	\$ 5,071	\$ 3,773
Growth rate	18 %	(3) %	2 %	2 %	34 %	13 %
Segment profit						
Amount	\$ 2,138	\$ 1,723	\$ 108	\$ 65	\$ 524	\$ 356
Growth rate	24 %	12 %	66 %	44 %	47 %	14 %
Segment profit margin	1.21 %	1.15 %	1.13 %	0.69 %	10.33 %	9.44 %

The sum of the components and certain computations may reflect rounding adjustments.



Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation - GAAP Cash Flow to Non-GAAP Adjusted Free Cash Flow

(in millions)	Third Quarter		Year-to-Date	
	2026	2025	2026	2025
GAAP - Cash Flow Categories				
Net cash provided by operating activities	\$ 1,823	\$ 2,924	\$ 3,482	\$ 877
Net cash used in investing activities	(181)	(2,898)	(2,303)	(3,962)
Net cash provided by/(used in) financing activities	(483)	(514)	(1,112)	1,277
Effect of exchange rates changes on cash and equivalents	1	4	(4)	1
Net increase/(decrease) in cash and equivalents	\$ 1,160	\$ (484)	\$ 63	\$ (1,807)
Non-GAAP Adjusted Free Cash Flow				
Net cash provided by operating activities	\$ 1,823	\$ 2,924	\$ 3,482	\$ 877
Repurchases of liability-classified Specialty Alliance Units	5	—	27	—
Additions to property and equipment	(146)	(126)	(385)	(315)
Payments related to matters included in litigation (recoveries)/charges, net	15	1	401	622
Non-GAAP Adjusted Free Cash Flow	\$ 1,697	\$ 2,799	\$ 3,525	\$ 1,184

For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.



Cardinal Health, Inc. and Subsidiaries

Distribution, Selling, General and Administrative ("SG&A") Expenses, excluding Acquisitions

<u>(in millions)</u>	Third Quarter			Year-to-Date		
	Consolidated			Consolidated		
	2026	2025	% Change	2026	2025	% Change
SG&A expenses	\$ 1,542	\$ 1,315	17 %	\$ 4,507	\$ 3,898	16 %
Less: Recent acquisitions ¹	216	80	N.M.	569	97	N.M.
SG&A expenses, excluding recent acquisitions	\$ 1,326	\$ 1,235	7 %	\$ 3,938	\$ 3,801	4 %

¹ Recent acquisitions include Integrated Oncology Network (December 2024), GI Alliance (January 2025), Advanced Diabetes Supply Group (April 2025), Urology America (May 2025), and Solaris Health (November 2025).



In this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company's routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.

The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company's fiscal 2026 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company's EPS from \$1.79 to \$8.44, which includes a \$6.79 charge related to the goodwill impairment charge for the GMPD segment in fiscal 2022.



Definitions

Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.

Interest and Other, net: other (income)/expense, net plus interest expense, net.

Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses).

Segment Profit margin: segment profit divided by segment revenue.

Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits).

Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessment related to prior fiscal years and shareholder cooperation agreement costs.

Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.

Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.

Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.

Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, each net of tax.

Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) acquisition-related cash and share-based compensation costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net, divided by (earnings before income taxes adjusted for the items above).

Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

Non-GAAP adjusted free cash flow: net cash provided by operating activities plus repurchases of liability-classified Specialty Alliance Units, less payments related to additions to property and equipment, excluding settlement payments and receipts related to matters included in litigation (recoveries)/charges, net, as defined above, or other significant and unusual or non-recurring cash payments or receipts.



Definitions continued

¹ LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies' financial results. We did not recognize any LIFO charges or credits during the periods presented.

² State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.

³ Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations.

⁴ Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current, and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity's initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity, and size of acquisitions.

⁵ Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs include fair value adjustments for liability-classified awards. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices.

⁶ Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results.

⁷ Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.

The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Non-GAAP adjusted free cash flow: We provide this non-GAAP financial measure as a supplemental metric to assist readers in assessing the effects of items and events on our cash flow on a year-over-year basis and in comparing our performance to that of our peer group companies. In calculating this non-GAAP metric, certain items are excluded from net cash provided by operating activities because they relate to significant and unusual or non-recurring events and are inherently unpredictable in timing and amount. We believe adjusted free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, debt repayments, dividend payments, share repurchases, strategic acquisitions, or other strategic uses of cash. A reconciliation of our GAAP financial results to Non-GAAP adjusted free cash flow is provided in Schedule 6 of the financial statement tables included with this release.

